Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Galapagos NV    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
11/24/2020 11/25/2020 11/26/2020 11/27/2020 11/30/2020 Date
104.8(c) 101.65(c) 105.4(c) 105.1(c) 104.25 Last
429 779 418 946 260 969 308 292 365 161 Volume
-0.29% -3.01% +3.69% -0.28% -0.81% Change
More quotes
Financials
Sales 2020 526 M 630 M 630 M
Net income 2020 -316 M -378 M -378 M
Net cash position 2020 3 596 M 4 307 M 4 307 M
P/E ratio 2020 -24,2x
Yield 2020 -
Sales 2021 523 M 626 M 626 M
Net income 2021 -360 M -432 M -432 M
Net cash position 2021 3 501 M 4 193 M 4 193 M
P/E ratio 2021 -23,9x
Yield 2021 -
Capitalization 6 867 M 8 211 M 8 225 M
EV / Sales 2020 6,22x
EV / Sales 2021 6,44x
Nbr of Employees 1 407
Free-Float 74,4%
More Financials
Company
Galapagos NV specializes in the research and development of drugs based on novel targets discovered and validated in human primary cells. Net sales break down by activity as follows: - discovery and development of drugs (98.8%); - other (1.2%). Net sales are distributed geographically as follows: Europe (5.8%) and North America (94.2%). 
More about the company
Notations Surperformance© of Galapagos NV
Trading Rating : Investor Rating :
More Ratings
All news about GALAPAGOS NV
11/23GALAPAGOS : Selvita to acquire Fidelta from Galapagos
AQ
11/23GALAPAGOS : Selvita to acquire Fidelta from Galapagos
AQ
11/09GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..
AQ
11/09GALAPAGOS : First patient dosed with GLPG3667 in psoriasis patient Phase 1b tria..
AQ
11/09First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
GL
11/09OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent ..
AQ
11/05GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..
AQ
11/05GALAPAGOS : OncoArendi and Galapagos enter into exclusive collaboration on chiti..
AQ
11/05OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhi..
GL
11/05GALAPAGOS : reports Q3 2020 results
AQ
11/05GALAPAGOS : reports Q3 2020 results
AQ
11/05Galapagos reports Q3 2020 results
GL
11/03GILEAD SCIENCES : European Medicines Agency Validates Marketing Application for ..
AQ
11/02GALAPAGOS : European Medicines Agency Validates Marketing Application for Filgot..
BU
11/02GALAPAGOS : European  medicines  agency  validates  marketing  application  for ..
AQ
More news
News in other languages on GALAPAGOS NV
11/09AVIS D'ANALYSTES DU JOUR : Amadeus, Cellnex, Eurazeo, Givaudan, Kering, Klépierr..
10/21AVIS D'ANALYSTES DU JOUR : Air Liquide, Continental, Galapagos, Logitech, Superd..
10/01TOUR DU MONDE DES INDICES : l’Aristocratie souffre sur le S&P500, la Santé sauve..
09/21TOUR DU MONDE DES INDICES : Les secteurs sont à l’honneur
08/25Vaccin, Chine, Election, le décor est planté
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Stock Trading Strategies
GALAPAGOS - 03/20
A support level that should be taken advantage of
BUY
More Stock Trading Analysis
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 127,11 €
Last Close Price 105,10 €
Spread / Highest target 52,2%
Spread / Average Target 20,9%
Spread / Lowest Target -0,10%
EPS Revisions
Managers
NameTitle
Onno van de Stolpe Chief Executive Officer & Executive Director
Raj B. Parekh Chairman
Bart Filius Chief Operating & Financial Officer
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS NV-43.65%8 211
MODERNA, INC.549.44%50 267
LONZA GROUP AG56.23%45 319
CELLTRION, INC.82.04%40 460
IQVIA HOLDINGS INC.9.26%32 365
SEAGEN INC.48.01%30 493